Our Iron Will: المراجع

المراجع

  1. Coates TD and Wood JC, How we manage iron overload in sickle cell patients. Br J Haematol. 2017 June; 177(5): 703-716
  2. Hider RC and Hoffbrand AV, The Role of Deferiprone in Iron Chelation. N Engl J Med 2018;379:2140-50
  3. Children’s Hospital & Research Center Oakland. Standards of Care Guidelines for Thalassemia 2012
  4. Coates TD. Physiology and pathophysiology of iron in hemoglobin-associated diseases. Free Radical Biology and Medicine 72(2014)23–40
  5. Beris P, Transfusion and Iron Overload: Where Are the Risks? HAEMA 2019; 10(1):29-38
  6. Borgna-Pignatti C et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. haematologica 2004;89:1187-1193
  7. Fung EB et al. Morbidity and Mortality in Chronically Transfused Subjects With Thalassemia and Sickle Cell Disease: A Report From the Multi-Center Study of Iron Overload. American Journal of Hematology (2007) 82:255–265
  8. Coates TD et al. Management of iron overload in hemoglobinopathies: what is the appropriate target iron level? Ann. N.Y. Acad. Sci. 1368 (2016) 95–106
  9. Pennell DJ, et al. Cardiovascular Function and Treatment in β-Thalassemia Major. A Consensus Statement From the American Heart Association. Circulation. 2013;128:281-308
  10. American Society of Hematology. Understanding Sickle Cell Disease. Available at: https://www.hematology.org/-/media/hematology/files/education/clinicians/guidelines-quality/documents/ash-understanding-scd-infographic_2019.pdf?la=en&hash=F96E476D04908727FD74678B5C876266
  11. National Heart, Lung and Blood Institute. Sickle Cell Disease. Available at: https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease
  12. Howard J, Sickle cell disease: when and how to transfuse. Hematology 2016
  13. Ballas SK et al. The effect of iron chelation therapy on overall survival in sickle cell disease and b-thalassemia: A systematic review. Am J Hematol. 2018; 93:943–952
  14. Sundaram N, et al. Biomarkers for early detection of sickle nephropathy. Am J Hematol. 2011 July ; 86(7): 559–566
  15. Wang W, et al. Serum Ferritin: Past, Present and Future. Biochim Biophys Acta. 2010 August ; 1800(8): 760–769
  16. Junqueira FP, et al. Right and left ventricular function and myocardial scarring in adult patients with sickle cell disease: a comprehensive magnetic resonance assessment of hepatic and myocardial iron overload. Journal of Cardiovascular Magnetic Resonance 2013, 15:83
  17. Muncie HL and Campbell JS. Alpha and Beta Thalassemia. American Family Physician. August 15, 2009 Volume 80, Number 4
  18. Marengo-Rowe AJ. The thalassemias and related disorders. Proc (Bayl Univ Med Cent) 2007;20:27–31
  19. Sheth S, Monitoring of Iron Overload in Transfusion-Dependent Thalassemia (TDT). NewYork-Presbyterian Hospital/Weill Cornell Medical Center
  20. Cappellini MD, et al. Guidelines for the management of transfusion dependent thalassaemia (tdt). Thalassaemia International Federation 2014. 3rd Edition
  21. Centers for Disease Control al Prevention. Living Well with Sickle Cell Disease. Available at: https://www.cdc.gov/ncbddd/sicklecell/healthyliving-living-well.html
  22. Baer K, A Guide to Living with Thalassemia. Cooley’s Anemia Foundation in collaboration with the Centers for Disease Control and Prevention
  23. Sidhu S, et al. Adherence to Iron Chelation Therapy and Its Determinants. IJHOSCR January 2021. 15(1)
  24. Chou ST, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood advances 28 January 2020; Volume 4, Number 2
  25. Centers for Disease Control al Prevention. Infections and Sickle Cell Disease. Available at: https://www.cdc.gov/ncbddd/sicklecell/healthyliving-prevent-infection.html
  26. UCSF Benioff Children’s Hospital Oakland. Northern California Comprehensive Thalassemia Center. Living with Thalassemia. Available at: https://thalassemia.com/nutrition-simple-suggestions.aspx#gsc.tab=0
  27. Fung EB, et al. Inadequate Dietary Intake in Patients with Thalassemia. J Acad Nutr Diet. 2012 July ; 112(7): 980–990
  28. Cunningham E. Journal of the Academy of Nutrition and Dietetics. 2016
  29. PCRM’s Nutrition Guide for Clinicians. Sickle Cell Disease. Available at: https://nutritionguide.pcrm.org/nutritionguide/view/Nutrition%20Guide%20for%20Clinicians/1342072/all/Sickle_Cell_Disease
  30.      

في حالة الحاجة إلى الإبلاغ عن تفاعل دوائي ضار، يُرجى الرجوع إلى طبيبك، واطلب منه ملء تقرير الحالة ذي الصلة وتقديمه إلى هيئة الصحة المعنية وفقًا لمتطلبات اليقظة الدوائية المعمول بها في دولتك. وعلى الرغم من ذلك، يُرجى التفضل بتذكر أنه يمكن لكل مريض الإبلاغ عن أي من تلك الحالات مباشرةً إلى نظام الإبلاغ الوطني.